SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic.

The previously announced date and time of the annual meeting, Monday, May 18, 2020, at 9:00 a.m. PT, has not changed. Stockholders will not be able to attend the annual meeting in person.

Whether or not stockholders plan to virtually attend the annual meeting, Sangamo urges them to vote and submit their proxy in advance of the annual meeting by one of the methods described in the proxy materials for the annual meeting.

The proxy card included with any proxy materials previously distributed will not be updated to reflect the change in location and may continue to be used to vote shares in connection with the annual meeting.

Attending and Voting at the Annual Meeting as a Stockholder of Record

At the time and date of the annual meeting, Sangamo stockholders of record as of March 20, 2020 (the ‘record date’) can attend and vote by accessing the meeting center at and entering the 15-digit control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. The meeting password is SGMO2020. Stockholders of record can vote their shares by clicking on the ‘Cast Your Vote’ link in the meeting center.

Registering to Attend and Vote at the Annual Meeting as a Beneficial Owner

Beneficial stockholders as of the record date (i.e., shares held in ‘street name’ through an intermediary, such as a bank or broker) must register in advance to attend and vote at the annual meeting. To register, stockholders must obtain a legal proxy from the holder of record and submit proof of legal proxy reflecting the number of shares of Sangamo common stock held as of the record date, along with name and email address, to Computershare at . Requests for registration must be labeled as “Legal Proxy” and must be received no later than Wednesday, May 13, 2020, 2:00 p.m. PT. Stockholders will then receive a confirmation of registration with a control number by email from Computershare. At the time and date of the annual meeting, registered beneficial stockholders can attend by accessing the meeting center at and entering the 15-digit control number received by email. The meeting password is SGMO2020. Registered beneficial owners can vote their shares by clicking on the ‘Cast Your Vote’ link in the meeting center.

Attending the Annual Meeting as a Guest

At the time and date of the annual meeting, guests can attend by accessing the meeting center at , clicking on the “I am a Guest” button and entering the information requested on the following screen.

Asking Questions

Stockholders of record and registered beneficial owners can submit questions to Sangamo’s representatives in the meeting center.

List of Stockholders of Record

At the time and date of the annual meeting, stockholders will be able to inspect a list of stockholders of record in the meeting center for any purpose germane to the annual meeting. Stockholders may also request to view a list of stockholders of record for ten days prior to the annual meeting by sending an email to .

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit .

EN
07/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sangamo Therapeutics Inc.

 PRESS RELEASE

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA f...

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway  Isaralgagene civaparvovec continues to show favorable safety and tolerability profile Sangamo expects to complete Biological License Application (BLA) submission under accelerated approval pathway in second quarter of 2026...

 PRESS RELEASE

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-5...

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. Fast Track Designation aims to facilitate the development and expedite the review of new the...

 PRESS RELEASE

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submissio...

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. This acceptance follows Sangamo’s meeting with the FDA...

 PRESS RELEASE

Sangamo Therapeutics Reports Recent Business Highlights and Third Quar...

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi...

 PRESS RELEASE

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company will hold a conference call at 8:30 a.m. Eastern on Thursday, November 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch